12:00 AM
 | 
Jul 03, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nolvadex tamoxifen regulatory update

The FDA granted marketing approval for AZN's Nolvadex to reduce the risk of invasive breast cancer in women...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >